NCT00681330 is a Phase 1/Phase 2 clinical trial of URC10, TTK, KOC1 in Esophageal Cancer, sponsored by Tokyo University.

Who is sponsoring NCT00681330?

NCT00681330 is sponsored by Tokyo University.

What drugs are being tested in NCT00681330?

Interventions in NCT00681330: URC10, TTK, KOC1.

What condition does NCT00681330 study?

NCT00681330 studies Esophageal Cancer.

Is NCT00681330 still recruiting?

NCT00681330 is currently completed. Last updated 18 November 2009.

Last reviewed 2009-11-18 · How we verify

NCT00681330

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Refractory Esophageal Cancer

Completed Phase 1/Phase 2 Last updated 18 November 2009

What this trial tests

Phase 1/Phase 2 trial testing URC10, TTK, KOC1 in Esophageal Cancer in 14 participants. Completed in 1 April 2009.

Timeline

1 May 2008

Primary endpoint
1 April 2009

1 April 2009

Quick facts

Lead sponsor	Tokyo University
Phase	Phase 1/Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	1 May 2008
Primary completion	1 April 2009
Estimated completion	1 April 2009
Sites	1 location across Japan

Drugs / interventions tested

URC10, TTK, KOC1 — full drug profile →

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →

Sponsor

Tokyo University

Who can join

Adults 20 to 85, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST)
Time frame: Two months

Sponsor's own description

The purpose of this study is to evaluate the safety and time to progression of HLA-A\*2402 restricted epitope peptides URLC10, TTK, and KOC1, emulsified with Montanide ISA 51.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Antigen-specific vaccines for cancer treatment.
Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, et al · · 2014 · cited 109× · PMID 25483639 · DOI 10.4161/21645515.2014.973317
Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer.
Naik A, Lattab B, Qasem H, Decock J. · · 2024 · cited 10× · PMID 38596293 · DOI 10.1016/j.omton.2024.200768
A narrative review of the emerging role of lymphocyte antigen 6 complex locus K in cancer: from basic research to clinical practice.
Guo D, Liu Y, Jiang Y, Zheng S, et al · · 2022 · cited 8× · PMID 35242871 · DOI 10.21037/atm-21-5831
Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer.
Shah BA, Holden JA, Lenzo JC, Hadjigol S, et al · · 2025 · cited 6× · PMID 40204832 · DOI 10.1038/s41541-025-01118-9
Chemical and Synthetic Biology Approaches for Cancer Vaccine Development.
Hossain F, Kandalai S, Zhou X, Zhang N, et al · · 2022 · cited 5× · PMID 36296526 · DOI 10.3390/molecules27206933
The role of N6-methyladenosine modification in tumor angiogenesis.
Qin L, Zeng X, Qiu X, Chen X, et al · · 2024 · cited 2× · PMID 39691597 · DOI 10.3389/fonc.2024.1467850

Verify or expand the search:

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Other Tokyo University trials

Trials by the same sponsor.

NCT07446894 — MSA-01 in Multiple System Atrophy · Phase 3 · recruiting
NCT07324265 — Pilot Cluster RCT of an Indirect Contact Mental Health Literacy Program for 5th-Grade Students · NA · not yet recruiting
NCT07106346 — Encapsulation-oriented vs. Timing-oriented Strategies for Necrotizing Pancreatitis · NA · not yet recruiting
NCT06135740 — Impact of Nutrition, Sleep, and Physical Activity on Intellectual Function and Muscle Mass in Older Adults · NA · completed
NCT05451901 — Immediate Necrosectomy vs. Step-up Approach for Walled-off Necrosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00681330 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tokyo University
Last refreshed: 18 November 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00681330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing